The cover picture shows an artistically refined computer graphic of the three-dimensional structure of verapamil, α-isopropyl-α-[(N-methyl-N-homoveratryl)-γ-aminopropyl]-3,4-dimethoxyphenylacetonitrile. This drug, which was developed in the research laboratories of Knoll AG, part of the BASF group, is used for treating high blood pressure, coronary heart disease, and certain types of heart-rhythm disturbances. When it was introduced for therapeutic use in 1963, Verapamil was the first calcium antagonist. Since then, other calcium antagonists have been found. They act by inhibiting the How of calcium ions into the cells of the heart muscle and thus improving the efficiency of its activity. They are also able to prevent cell damage when the blood supply to the heart is deficient, for example, during heart attacks. The picture represents the ideal way of developing a drug: starting from the desired biological action, scientists in a wide variety of disciplines employ the most up-to-date chemical, biological, and molecular-modeling methods in the rational design of an active substance. Indeed, this high degree of cooperation between disciplines applies very generally to most areas of basic and, especially, applied research. In seeking an innovative solution to a problem, applied research must take into consideration, on the one hand, the results of basic research and. on the other, the specific requirements of the market and a knowledge of the business. BASF celebrated its 125th anniversary with a symposium entitled “Chemistry for the Future—State of the Art and Perspectives”. This month's issue is based on 15 of the 18 lectures. It focuses on the future prospects of classical and interdisciplinary research in chemistry with particular emphasis on close cooperation between basic and applied research.